TMR Predominantly Used Off Label With CABG, FDA-Backed Study Shows
This article was originally published in The Gray Sheet
Executive Summary
The preponderance of cases in which transmyocardial revascularization is performed with cardiac artery bypass grafts signals a need for additional research on the off-label procedure, according to a study published in the Nov. 5 Journal of the American College of Cardiology
You may also be interested in...
TMR During Coronary Bypass: CMS Convenes MCAC To Reconsider Coverage
CMS should gather more prospective clinical trial data on transmyocardial revascularization during cardiac bypass surgery (TMR + CABG) before considering changes to its TMR Medicare coverage policy, the Society of Thoracic Surgery argues
TMR During Coronary Bypass: CMS Convenes MCAC To Reconsider Coverage
CMS should gather more prospective clinical trial data on transmyocardial revascularization during cardiac bypass surgery (TMR + CABG) before considering changes to its TMR Medicare coverage policy, the Society of Thoracic Surgery argues
CMS Exploring Effect On Clinical Care Of NCDs For TMR, PET, Cryosurgery
The effect of previous national coverage decisions (NCDs) on clinical care of patients receiving certain transmyocardial revascularization (TMR), oncology positron emission tomography (PET) and prostate cancer cryosurgery treatments will be explored by CMS, according to Office of Clinical Standards and Quality Acting Deputy Director Sean Tunis